Amphastar Pharmaceuticals (DE:29A)
FRANKFURT:29A
Holding DE:29A?
Track your performance easily

Amphastar Pharmaceuticals (29A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

29A Analyst Ratings

Moderate Buy
3Ratings
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Amphastar
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

29A Stock 12 Month Forecast

Average Price Target

€63.99
▲(47.21% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is €63.99 with a high forecast of €65.87 and a low forecast of €62.11. The average price target represents a 47.21% change from the last price of €43.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","42":"€42","50":"€50","58":"€58","66":"€66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65.8735,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€65.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.9914,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€63.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.1093,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€62.11</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,42,50,58,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46,47.52873076923077,49.05746153846154,50.58619230769231,52.11492307692308,53.643653846153846,55.172384615384615,56.70111538461539,58.229846153846154,59.75857692307693,61.28730769230769,62.81603846153847,64.34476923076923,{"y":65.8735,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46,47.383953846153844,48.767907692307695,50.15186153846154,51.53581538461538,52.919769230769234,54.30372307692308,55.68767692307692,57.071630769230765,58.455584615384616,59.83953846153846,61.22349230769231,62.607446153846155,{"y":63.9914,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46,47.239176923076926,48.478353846153844,49.71753076923077,50.95670769230769,52.195884615384614,53.43506153846154,54.674238461538465,55.913415384615384,57.1525923076923,58.39176923076923,59.63094615384615,60.87012307692308,{"y":62.1093,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.4,"date":1699574400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.5,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.6,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.91,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.49,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.14,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.26,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.61,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.56,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.53,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€65.87Average Price Target€63.99Lowest Price Target€62.11
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
€58.35€51.76
Buy
19.07%
Upside
Reiterated
08/12/24
Amphastar Pharmaceuticals (AMPH) PT Lowered to $55 at JefferiesJefferies analyst Glen Santangelo lowered the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $55.00 (from $62.00) while maintaining a Buy rating.
Bank of America Securities
€47.05€45.17
Hold
3.91%
Upside
Reiterated
08/08/24
Amphastar Pharmaceuticals Hold Rating Affirmed Amid Competitive Pressures and Pipeline Challenges
DBS
€51.76
Buy
19.07%
Upside
Reiterated
11/24/23
Analysts' Top Healthcare Picks: Autolus Therapeutics (AUTL), Amphastar Pharmaceuticals (AMPH)
J.P. Morgan Analyst forecast on DE:29A
Ekaterina Knyazkova
Not Ranked
J.P. Morgan
€56.46
Buy
29.89%
Upside
Initiated
03/05/24
Amphastar initiated with an Overweight at JPMorganAmphastar initiated with an Overweight at JPMorgan

Best Analysts Covering Amphastar Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy DE:29A and Sell After:
1 Month
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+2.77%
assigned a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +2.77% per trade.
3 Months
xxx
Success Rate
14/27 ratings generated profit
52%
Average Return
+2.03%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 51.85% of your transactions generating a profit, with an average return of +2.03% per trade.
1 Year
Tim ChiangCapital One Financial
Success Rate
15/18 ratings generated profit
83%
Average Return
+26.29%
assigned a buy rating 28 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +26.29% per trade.
2 Years
xxx
Success Rate
16/18 ratings generated profit
89%
Average Return
+53.62%
assigned a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +53.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

29A Analyst Recommendation Trends

Rating
Jun 24
Jul 24
Aug 24
Oct 24
Nov 24
Strong Buy
6
6
4
3
2
Buy
0
0
2
3
4
Hold
5
4
3
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
10
9
9
9
In the current month, 29A has received 6 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 29A average Analyst price target in the past 3 months is €63.99.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

29A Financial Forecast

29A Earnings Forecast

Next quarter’s earnings estimate for 29A is €0.91 with a range of €0.83 to €1.17. The previous quarter’s EPS was €0.90. 29A beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.62% of the time in the same period. In the last calendar year 29A has Underperformed its overall industry.
Next quarter’s earnings estimate for 29A is €0.91 with a range of €0.83 to €1.17. The previous quarter’s EPS was €0.90. 29A beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 59.62% of the time in the same period. In the last calendar year 29A has Underperformed its overall industry.

29A Sales Forecast

Next quarter’s sales forecast for 29A is €180.96M with a range of €176.60M to €184.83M. The previous quarter’s sales results were €179.57M. 29A beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year 29A has Outperformed its overall industry.
Next quarter’s sales forecast for 29A is €180.96M with a range of €176.60M to €184.83M. The previous quarter’s sales results were €179.57M. 29A beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year 29A has Outperformed its overall industry.

29A Stock Forecast FAQ

What is DE:29A’s average 12-month price target, according to analysts?
Based on analyst ratings, Amphastar Pharmaceuticals’s 12-month average price target is €63.99.
    What is DE:29A’s upside potential, based on the analysts’ average price target?
    Amphastar Pharmaceuticals has 47.21% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Amphastar Pharmaceuticals a Buy, Sell or Hold?
          Amphastar Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Amphastar Pharmaceuticals’s share price target?
            The average share price target for Amphastar Pharmaceuticals is €63.99. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €65.87 ,and the lowest forecast is €62.11. The average share price target represents 47.21% Increase from the current price of €43.47.
              What do analysts say about Amphastar Pharmaceuticals?
              Amphastar Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Amphastar Pharmaceuticals?
                To buy shares of DE:29A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis